Thank you, Anders. So, starting with Buvidal, the quarter was in line with our guidance assumptions. Reported sales of 422 million SEK were down 13% year on year, or 7% on a constant exchange rate basis, which reflects the UK channel phasing we've discussed. The more meaningful metric is in-market sales, which grew 17% year on year. So underlying demand is strong.
Nordics, Germany, France and Spain saw robust growth and Portugal saw rapid initial uptake following the release of funding to the treating clinics.
Overall healthcare professional and patient response in Portugal has been very positive, as we've seen in other markets.
In Australia, we saw the usual seasonal softness from the summer period. Sales there typically build in Q4 ahead of the vacations before normalizing in Q1. The UK remains a focus area. Funding restraints from the prior year carried into Q1, but importantly, a new three-year budget was announced for the NHS financial year starting the 1st of April. We expect this to lead to meaningfully improved patient access going forward, and during the quarter, some notable policy support for Buvidal was published in both England and Wales, with calls for more access and funding for long-acting buprenorphine. In Germany, the Federal Audit Office, which carries significant weight politically, has recommended shifting physician remuneration for opioid dependence treatment away from dispensing payments towards consultation and coordination of services, and has called on the Ministry of Health to update the reimbursement framework accordingly.
If and when implemented. When implemented, this structural change is expected to remove a key barrier to patient access to innovative treatments for opioid dependence.
And at the end of the quarter, approximately 73,000 patients were estimated to be in treatment with Buvidal, and we continued working towards our 2027 ambition of 100,000 patients. Now, turning to the US, Brixadi royalties in Q1 were 106 million SEK, up 44% year on year and 59% at constant exchange rates. The quarter did see some seasonal softness from prior annual prior authorization renewals and payer mix dynamics, both of which we expect to normalize as the year progresses and the underlying trajectory remains very strong. Brixadi's equivalent unit share reached approximately 32% of the US long-acting injectable buprenorphine segment, according to external audit data, which is up from 26% a year ago. And the segment itself is growing more than 30% year on year. So we're gaining share in an expanding market.
Braeburn continues to invest materially in the franchise, including expanded patient-facing commercial activities, and we remain confident in a strong trajectory through 2026. Now, moving across to the launch of Oczyesa in Germany, where we had a good first full quarter, sales reached 4.2 million SEK, with approximately 50 patients in treatment, representing about 2.5% share after just one quarter.
The product profile is resonating with both patients and physicians, and whilst we anticipate the rate of uptake to normalize going forward due to the cadence of patients visiting clinics, we continue to expect penetration towards a double-digit share in Germany by year-end.
Beyond Germany, launch preparations are advancing in the UK. We've secured listing on the NHS National Framework Agreement and have submitted 13 formal applications, and pricing approvals are in place in Norway and Sweden, and sales and medical teams are in place across our wave one markets.
The opportunity in initial launch markets is an estimated 3 to 5000 patients on current standard of care. Somatostatin analogues and market research indicates a 30 to 60% willingness to switch.
Now, turning to Oclaiz in the US, with the FDA PDUFA action date less than a month from today, our US commercial team organization is launch ready.
The core team has spent the last year executing a comprehensive pre-launch plan across every workstream. With these foundations in place, we are well positioned for an anticipated US launch of Oclaiz in Q3 2026.
With this, I'll hand back to Fredrik for the R&D update.